Do you want to skip to content? Skip to content
Convatec Group Contact Us Brasil Brasil United States (English) United States (English) Estados Unidos (Español) Estados Unidos (Español) Argentina Argentina Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Ecuador Ecuador México México Perú Perú Belize Belize Guyana Guyana Jamaica Jamaica Venezuela Venezuela Costa Rica Costa Rica Curaçao Curaçao República Dominicana República Dominicana Guatemala Guatemala Honduras Honduras Nicaragua Nicaragua Panamá Panamá Puerto Rico Puerto Rico Suriname Suriname El Salvador El Salvador United Kingdom United Kingdom France France Deutschland Deutschland Italia Italia Україна Україна België België Česko Česko Danmark Danmark España España Ireland Ireland Nederland Nederland Norge Norge Österreich Österreich Polska Polska Schweiz (Deutsch) Schweiz (Deutsch) Slovensko Slovensko Suisse (Français) Suisse (Français) Suomi Suomi Sverige Sverige Türkiye Türkiye Ελλάδα Ελλάδα Россия Россия Bosna i Hercegovina Bosna i Hercegovina България България Eesti Eesti Hrvatska Hrvatska Magyarország Magyarország Ísland Ísland Lietuva Lietuva Latvija Latvija Северна Македонија Северна Македонија Malta Malta România România Srbija Srbija Slovenija Slovenija الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين مصر مصر ישראל ישראל ایران ایران الأردن الأردن عُمان عُمان قطر قطر پاکستان پاکستان لبنان لبنان الكويت الكويت المملكة العربية السعودية المملكة العربية السعودية Suid-Afrika Suid-Afrika العراق العراق New Zealand New Zealand 日本 日本 Australia Australia India India Malaysia Malaysia Singapore Singapore 대한민국 대한민국 中国大陆 中国大陆 中国台湾 中国台湾 ไทย ไทย Indonesia Indonesia Việt Nam Việt Nam Philippines Philippines Hong Kong SAR China (English) Hong Kong SAR China (English) 中国香港特别行政区 (中文(简体,中国香港特别行政区)) 中国香港特别行政区 (中文(简体,中国香港特别行政区))
False /oidc-signin/en-gb/ Convatec Group Contact Us Brasil Brasil United States (English) United States (English) Estados Unidos (Español) Estados Unidos (Español) Argentina Argentina Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Ecuador Ecuador México México Perú Perú Belize Belize Guyana Guyana Jamaica Jamaica Venezuela Venezuela Costa Rica Costa Rica Curaçao Curaçao República Dominicana República Dominicana Guatemala Guatemala Honduras Honduras Nicaragua Nicaragua Panamá Panamá Puerto Rico Puerto Rico Suriname Suriname El Salvador El Salvador United Kingdom United Kingdom France France Deutschland Deutschland Italia Italia Україна Україна België België Česko Česko Danmark Danmark España España Ireland Ireland Nederland Nederland Norge Norge Österreich Österreich Polska Polska Schweiz (Deutsch) Schweiz (Deutsch) Slovensko Slovensko Suisse (Français) Suisse (Français) Suomi Suomi Sverige Sverige Türkiye Türkiye Ελλάδα Ελλάδα Россия Россия Bosna i Hercegovina Bosna i Hercegovina България България Eesti Eesti Hrvatska Hrvatska Magyarország Magyarország Ísland Ísland Lietuva Lietuva Latvija Latvija Северна Македонија Северна Македонија Malta Malta România România Srbija Srbija Slovenija Slovenija الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين مصر مصر ישראל ישראל ایران ایران الأردن الأردن عُمان عُمان قطر قطر پاکستان پاکستان لبنان لبنان الكويت الكويت المملكة العربية السعودية المملكة العربية السعودية Suid-Afrika Suid-Afrika العراق العراق New Zealand New Zealand 日本 日本 Australia Australia India India Malaysia Malaysia Singapore Singapore 대한민국 대한민국 中国大陆 中国大陆 中国台湾 中国台湾 ไทย ไทย Indonesia Indonesia Việt Nam Việt Nam Philippines Philippines Hong Kong SAR China (English) Hong Kong SAR China (English) 中国香港特别行政区 (中文(简体,中国香港特别行政区)) 中国香港特别行政区 (中文(简体,中国香港特别行政区))

Disrupts, destroys, and prevents biofilm re-formation

1,2

Request your free sample

Biofilm is present in 78% of hard-to-heal wounds and a primary barrier to healing3

  • Biofilm delays wound healing.4
  • Exudate and slough allow biofilm to develop and thrive.3
  • Bioflim provides tolerance to antimicrobial agents and can result in persistent inflammation and infection.5

To prevent biofilm reformation on wound bed, effective long-lasting antimicrobial protection is needed.6

A green single-eyed slime monster is used to represent biofilm. ;

 Aquacel® Ag+ Extra™ specifically designed to meet the unmet need of effective biofilm action.2

Aquacel® Ag+ Extra™ combines two powerful healing technologies:  MORE THAN SILVER™ and Hydrofiber™3
Request your free sample

Hydrofiber™ Technology

Hydrofiber™ Technology forms a cohesive gel that absorbs and retains exudate, inflammatory proteases, debris, microorganisms8 and disrupted biofilm.3

Hydrofiber™ Technology logo, a soft and absorbent material that transforms into a gel on contact with wound fluid. ;

MORE THAN SILVER™

BEC8, a surfactant, reduces the surface tension within a biofilm to enhance the anti-biofilm performance of Aquacel® Ag+ Extra™ dressing.3,5

EDTA9,10, a metal chelating agent, EDTA helps disrupt biofilm by removing metal ions that hold the EPS matrix together to expose microorganisms to the antimicrobial effects of the ionic silver.3,6

IONIC SILVER11,12, a broad-spectrum antimicrobial contained in a safe and effective quantity (1.2%) ensures cell death of the exposed bacteria by damaging the DNA, denaturing proteins and enzymes, and interfering with protein synthesis.2,7

Developing MORE THAN SILVER™ technology involved researching a wide range of biofilm-disrupting agents and surfactants in combination with antimicrobials.2

A circular diagram with sections labelled "EDTA", "IONIC SILVER", and "BEC" describes working together to disrupt biofilms. ;

Efficacy proven in lab with validated methodology13-15

MORE THAN SILVER™ technology in Aquacel® Ag+ Extra™ dressing delivers superior anti-biofilm activity compared to other silver-containing gelling fibre dressings.14-16

Aquacel® Ag+ Extra™ dressing significantly reduced fungal biofilm and polymicrobial biofilm to below the limit of detection for 72 hours.14
A bar graph showing Aquacel® Ag+ Extra™ dressing in reducing fungal and polymicrobial biofilms compared to other dressings. ; Bar graph showing Aquacel® Ag+ Extra™ dressing in reducing fungal and candida albicans biofilms compared to other dressings. ;

New Lab evidence

In recent new lab evidence, Aquacel® Ag+ Extra™ demonstrated improved antibiofilm activity compared to other silver dressings and was the only to reduce the biofilm populations below the limit of detection (by 96 hours).15
A line graph shows that Aquacel Ag+ Extra reduces Pseudomonas aeruginosa at 96 hours compared to other wound dressings. ; A line graph showing Aquacel Ag+ Extra™ compared to other silver dressings in reducing biofilm bacteria over time. ;

Aquacel® Ag+ Extra™ reduced biofilm population within 24 hours and exhibited gradual reduction in biofilm population over the test period.16

The enhanced antibiofilm activity of Aquacel® Ag+ Extra™ dressing may be attributed to the additional antibiofilm agents contained within the dressing.17
A line graph showing the Aquacel Ag+ Extra™ dressings against a dual-species biofilm of CA-MRSA and K. pneumoniae. ;

Clinically proven in real world

Aquacel® Ag+ Extra™ supports wound progression and healing in static and deteriorating hard-to-heal wounds17
A chart shows wound healing improvement categorised as deteriorating, stagnant/same, improving, healed, and not classified. ;
A smiling face with two hearts inside a circle indicates that 78% of wounds showed improved healing within 4 weeks.

78% of wounds are healed or progressed within 4 weeks.16

Two medical professionals standing side-by-side indicate that 99% of clinicians recommend Aquacel® Ag+ Extra™ dressing.

99% of clinicians would recommend the use of Aquacel® Ag+ Extra™ dressing.16

Ordering codes

Request your free sample

Indications1

  • Leg ulcers, including:

    - venous stasis ulcers 
    - arterial ulcers 
    - leg ulcers of mixed aetiology
  • Diabetic foot ulcers
  • Pressure ulcers/injuries
  • Surgical wounds
  • Traumatic wounds
  • Malignant wounds
  • Partial thickness burns
Aquacel™ Ag+ Extra and Aquacel™ Ag+ Ribbon Dressing with Hydrofiber™ Technology and Ag+ Technology - a unique ionic silver. ;
Dressing size Pack size Product Name Product code
5 x 5cm 10 Aquacel® Ag+ Extra™ 413566
10 x 10cm 10 Aquacel® Ag+ Extra™ 413567
15 x 15cm 5 Aquacel® Ag+ Extra™ 413568
20 x 30cm 5 Aquacel® Ag+ Extra™ 413569
4 x 10cm 10 Aquacel® Ag+ Extra™ 413581
4 x 20cm 10 Aquacel® Ag+ Extra™ 413598
4 x 30cm 10 Aquacel® Ag+ Extra™ 413599

 

Dressing size Pack size Product Name Product code
1 x 45cm Ribbon 5 Aquacel® Ag+ Ribbon (for cavity wounds) 413570
2 x 45cm Ribbon 5 Aquacel® Ag+ Ribbon (for cavity wounds) 413571

Reference:
AWC-2023-036 More Than Silver™ antibiofilm technology differentiates Aquacel® Ag+ and Aquacel™ Ag Advantage dressings from standard silver-containing dressings. Data on File. 
1. 1708881v1 Instruction for Use, Convatec. 
2. Bowler PG, Parsons, D. Combatting wound biofilm and recalcitrance with a novel anti-biofilm Hydrofiber® wound dressing. Wound Medicine 14 (2016) 6–11. 
3. Murphy C, Atkin L, Vega de Ceniga M, Weir D, Swanson T. International consensus document. Embedding Wound Hygiene into a proactive wound healing strategy. J Wound Care 2022;31:S1–S24. 
4. Gurjala AN et al. Development of a novel, highly quantitative in vivo model for the study of biofilmimpaired cutaneous wound healing. Wound Rep Reg (2011) 19 400-410. 
5. Hall-Stoodley L I et al. Towards diagnostic guidelines for biofilm-associated infections. FEMS Immunol Med Microbiol. 2012; 65:127–145. 
6. Wolcott RD et al. Biofilm maturity studies indicate sharp debridement opens a time dependent therapeutic window. J Wound Care. 2010. 
7. Walker et al. Scanning electron microscopic examination of bacterial immobilisation in a carboxymethyl cellulose (AQUACEL®) and alginate dressing. Biomaterials 2003; 24:883-90. 
8. Parsons. Composition comprising antimicrobial metal ions and a quaternary cationic surfactant. WO2012136968A1. 
9. Banin et al. Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in Biofilm. Appl. Environ. Microbiol 2006; 72: 2064-2069. 
10. Finnegan & Percival. EDTA: an antimicrobial and antibiofilm agent for use in wound care. Adv Wound Care (New Rochelle) 2015; 4: 415–421. 
11. Lansdown. Silver 1: Its antibacterial properties and mechanisms of action. J Wound Care 2002; 11: 125-130. 
12. Lansdown. The role of silver. Eur Tissue Rep Soc 2002; 9: 108-111. 
13. Suleman L, Purcell L, Thomas H, Westgate S. Use of internally validated in vitro biofilm models to assess antibiofilm performance of silver-containing gelling fibre dressings. J Wound Care. 2020 Mar 2;29(3):154-161. doi: 10.12968/jowc.2020.29.3.154. PMID: 32160088. 
14. Meredith K, Coleborn MM, Metcalf DG. Assessment of Silver-Containing Gelling Fiber Dressings Against Antibiotic-Resistant Pathogens Using an in vitro Biofilm Model. Infect Drug Resist. 2023 Nov 2;16:7015-7019. doi: 10.2147/IDR.S433981. PMID: 37937098; PMCID: PMC10627251. 
15. Meredith K, Coleborn MM, Forbes M., Metcalf DG. The antibiofilm activity of antimicrobial dressings against dual-species biofilm. Poster at Wounds UK Conference, November 2023,Harrogate, UK
16. Metcalf DG, Parsons D, Bowler PG. Clinical safety and effectiveness evaluation of a new antimicrobial wound dressing designed to manage exudate, infection and biofilm. Int Wound J. 2017

You are leaving convatec.com

This Internet site may provide links or references to other sites but Convatec have no responsibility for the content of such other sites and shall not be liable for any damages or injury arising from that content. Any links to other sites are provided as merely a convenience to the users of this Internet site.

Do you wish to continue?